Dataset Information

EGF drug resistance in Hela cells

ABSTRACT: Study gefitinib resistance-related proteins in hela cells

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

DISEASE(S): Cervix Carcinoma

SUBMITTER: chunchao zhang

LAB HEAD: Jun Qin

PROVIDER: PXD006296 | Pride | 2018-03-19

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	HeLa_Starv_EGF_2h_TFRE_EXP1.msf	Msf
	HeLa_Starv_EGF_2h_TFRE_EXP1_F1.raw	Raw
	HeLa_Starv_EGF_2h_TFRE_EXP1_F2.raw	Raw
	HeLa_Starv_EGF_2h_TFRE_EXP2.msf	Msf
	HeLa_Starv_EGF_2h_TFRE_EXP2_F1.raw	Raw

Items per page:

1 - 5 of 115

Publications

A Bioinformatic Algorithm for Analyzing Cell Signaling Using Temporal Proteomic Data.

Zhang Chunchao C Chen Yue Y Mao Xinfang X Huang Yin Y Jung Sung Yun SY Jain Antrix A Qin Jun J Wang Yi Y

Proteomics 20171101 22

Significance analysis of proteomic data generated by LC-MS/MS is challenging owing to great data variability originated from biological, operational, and instrumental variations. Protein quantification by LC-MS/MS either in absolute or relative scale is often highly skewed, which put limitations on model-based statistical inference. For this purpose, we have developed an alternative nonparametric statistical algorithm (named IQR algorithm) for significance analysis of temporal proteomic data and ...[more]

PMID: 28940701

Similar Datasets

Project description:Postmenopausal breast cancer patients benefit from aromatase inhibitors (AIs) that reduce the levels of estrogens critical for the growth of estrogen receptor (ER)-positive tumors. Unfortunately, many tumors are resistant to AI, and we are only beginning to understand the complex mechanisms underlying treatment resistance. Here we set out to determine whether epigenetic changes could contribute to therapy resistance. For AI-resistance models, we used previously established MCF-7 cell clones, termed C4-12 and long-term estrogen deprivation (LTED), that were isolated after being cultured in estrogen-free media for 9 months and 18M-bM-^@M-^S24 months, respectively. Methyl CpG Binding Domain (MBD) - pull down followed by affymetrix promoter array was used to detect promoter methylation patterns in these cell lines. These studies identified widespread genomic hyper- and hypomethylation events, with a significant enrichment of promoter hypermethylation of development-associated genes in both cell lines. A developmentally regulated gene that was heavily methylated and lost expression in both cell-line systems was HOXC10. Moreover, we found that HOXC10 is an estrogen-regulated gene and lack of ER regulation is associated with progressive epigenetic silencing through EZH2/H3K27me3 and DNA hypermethylation. Stable knockdown of HOXC10 in MCF-7 cells resulted in increased cell growth, reduced cell apoptosis, and increased cell motility. A preliminary study using AI-treated breast tumors did not show significant associations, however, the numbers were small. We identified HOXC10 methylation as a novel determinant of endocrine resistance. Also, we revealed that epigenetic reprogramming of genes involved in development may be a fundamental phenomenon in hormone resistance. Therefore, our study might provide the basis for the expansion of clinical markers for endocrine resistance and future clinical trials such as combination of endocrine and epigenetic therapies. Long-term estrogen deprived previously established MCF-7 cell clones termed C4-12 and LTED genomic DNA subjected to Methyl CpG Binding Domain (MBD) - pull down followed by affymetrix promoter array to detect promoter methylation patterns